Take this for what it is worth. But I find it strange that an estrogen can increase LH in women. I have also read that estriol can be used instead of nolvadex for breast cancer. So these things might suggest a blocking action of estradiol.
When I took PREG or DHEA things got worse. Withing hours of taking PREG I would get depression sad emotion and suicidal thoughts. And the DHEA made twitches WAY worse. I figured that these problems were related to
excess conversion to estradiol.
So then I tried a estrogen cream with 8 times as much estriol as estradiol. I only tried it once. But felt fine. Not depression, nothing bad like when I took the preg. This had me stumped. Maybe bad absorbtion or too low a dose. I did not take it again since then.
But I purchased estriol cream. I put it on 20 minutes ago. Hard to say what will happen.
Estriol administration modulates luteinizing hormone secretion in women with functional hypothalamic amenorrhea
Posted by carlaasrm on Thursday, May 31, 2012 · Leave a Comment
Capsule:
Estriol administration modulates the hypothalamuspituitary unit and promotes the recovery of luteinizing hormone synthesis and secretion in functional hypothalamic amenorrhea.
Authors:
Alessandro D. Genazzani, M.D., Ph.D., Blazej Meczekalski, M.D., Agnieszka Podfigurna-Stopa, M.D., Susanna Santagni, M.D., Erica Rattighieri, M.D., Federica Ricchieri, M.D., Elisa Chierchia, M.D., Tommaso Simoncini, M.D., Ph.D.
Volume 97, Issue 2 , Pages 483-488, February 2012
Objective:
To evaluate the influence of estriol administration on the hypothalamus-pituitary function and gonadotropins secretion in patients affected by functional hypothalamic amenorrhea (FHA).
Design:
Controlled clinical study.
Setting:
Patients with FHA in a clinical research environment.
Patient(s):
Twelve hypogonadotropic patients affected by FHA.
Intervention(s):
Pulsatility study of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and a gonadotropin-releasing hormone (GnRH) test (10 μg in bolus) at baseline condition and after 8 weeks of therapy with 2 mg/day of estriol.
Main Outcome Measure(s):
Measurements of plasma LH, FSH, estradiol (E2), androstenedione (A), 17α-hydroxyprogesterone (17-OHP), cortisol, androstenedione (A), testosterone (T), thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), and insulin, and pulse detection.
Result(s):
After treatment, the FHA patients showed a statistically significant increase of LH plasma levels (from 0.7 ± 0.1 mIU/mL to 3.5 ± 0.3 mIU/mL) and a statistically significant increase of LH pulse amplitude with no changes in LH pulse frequency. In addition, the LH response to the GnRH bolus was a statistically significant increase.
Conclusion(s):
Estriol administration induced the increase of LH plasma levels in FHA and improved GnRH-induced LH secretion. These findings suggest that estriol administration modulates the neuroendocrine control of the hypothalamus-pituitary unit and induces the recovery of LH synthesis and secretion in hypogonadotropic patients with FHA.